Javier Bolanos-Meade
Overview
Explore the profile of Javier Bolanos-Meade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
4758
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Siegel S, DeWolf S, Schmalz J, Saber W, Dong J, Martens M, et al.
medRxiv
. 2025 Mar;
PMID: 40061351
Successful hematopoietic cell transplant requires immunosuppression to prevent graft-versus-host disease (GVHD), a lethal, T-cell-mediated post-transplant complication. The phase 3 BMT CTN 1703 trial demonstrated superior GVHD-free/relapse-free survival for post-transplant cyclophosphamide...
2.
Lee J, Norman H, Ziggas J, Bolanos-Meade J, Porter T
Transplant Cell Ther
. 2025 Mar;
PMID: 40043847
Post-transplantation cyclophosphamide (PTCy) is standard graft-versus-host disease (GVHD) prophylaxis for allogeneic blood or marrow transplantation (alloBMT), although optimal therapeutic levels of immunosuppression (IS) therapy combined with PTCy remain contested. Previously,...
3.
Holtan S, Bolanos-Meade J, Al Malki M, Wu J, Kitko C, Reshef R, et al.
J Clin Oncol
. 2025 Jan;
43(8):912-918.
PMID: 39752608
The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free survival (GRFS)...
4.
Tabbara N, Zahurak M, Zahurak M, Sterling C, Sterling C, Trutzer I, et al.
Blood Adv
. 2024 Dec;
9(5):1202-1209.
PMID: 39693511
Patients with relapsed classic Hodgkin lymphomas (cHLs) receive salvage therapy with immune checkpoint inhibitors (ICIs) or chemotherapy (no-ICI). Patients responding to therapy often undergo consolidation with allogeneic blood or marrow...
5.
Bolanos-Meade J
Transplant Cell Ther
. 2024 Nov;
30(11):1045-1046.
PMID: 39505471
No abstract available.
6.
Shaffer B, Gooptu M, DeFor T, Maiers M, Bolanos-Meade J, Abboud R, et al.
J Clin Oncol
. 2024 Jul;
42(28):3277-3286.
PMID: 39018507
PURPOSEAccess to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease...
7.
Meade M, Bolanos-Meade J
Hematology
. 2024 Apr;
29(1):2346401.
PMID: 38687632
Allogeneic bone marrow transplantation is a curative intervention for both neoplastic and non-malignant conditions. However, not all patients have an HLA-matched donor. Therefore, the development of an approach that expand...
8.
Klausner M, Phan B, Morsberger L, Parish R, Shane A, Park R, et al.
Blood Cancer J
. 2023 Nov;
13(1):163.
PMID: 37926709
No abstract available.
9.
Bolanos-Meade J, Hamadani M, Wu J, Al Malki M, Martens M, Runaas L, et al.
N Engl J Med
. 2023 Jun;
388(25):2338-2348.
PMID: 37342922
Background: In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease (GVHD). A phase 2 study indicated the potential...
10.
DeZern A, Zahurak M, Symons H, Cooke K, Huff C, Jain T, et al.
Blood
. 2023 Apr;
141(25):3031-3038.
PMID: 37084383
Severe aplastic anemia (SAA) is a marrow failure disorder with high morbidity and mortality. It is treated with bone marrow transplantation (BMT) for those with fully matched donors, or immunosuppressive...